UPDATE: Morgan Stanley On Cyteir Therapeutics Overweight Initiation: Initial CYT-0851 Phase Data Have Been Encouraging In A Heavily-Penetrated Population, With Responses Observed In multiple Tumor Types While Maintaining A Favorable Safety Profile